Clinical Trials

Phase 1 Active not recruiting

Plasma cell

Recurrence, Neoplasms, Plasma Cell

NCT04608487 2025-07-30

Axi-cel in CNS Lymphoma

18 enrolled

Lymphoma, Recurrence

NCT06838832 2025-07-30

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Phase 1/2 Recruiting

30 enrolled

Recurrence

NCT05963217 2025-07-02

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Phase 1 Recruiting

19 enrolled

Phase 1 Active not recruiting

Immune System Diseases, Lymphoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03766126 2025-06-26

Lentivirally Redirected CD123 Autologous T Cells in AML

22 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT06802315 2025-06-25

BMT-13

Phase 2 Recruiting

38 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT01822652 2025-02-24

GRAIN

Phase 1 Active not recruiting

11 enrolled

CNS

Neuroblastoma, Recurrence

NCT06834529 2025-02-19

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

Phase 1/2 Recruiting

Phase NA Not yet recruiting

Lymphoma, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

NCT03658785 2024-08-13

Immunotherapy for the Treatment of Advanced Solid Tumor

Phase 1/2 Recruiting

40 enrolled

Neoplasm Metastasis, Recurrence

NCT06385808 2024-04-26

Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML

37 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT03056339 2024-03-25

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Phase 1/2 Completed

49 enrolled 12 charts

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03215810 2023-07-24

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

20 enrolled 10 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Recurrence, Carcinoma, Adenosquamous

NCT02431988 2023-04-28

COBALT

10 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05797948 2023-04-04

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase NA Unknown

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Recurrence, Lymphoma, B-Cell

NCT04706936 2023-02-06

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Phase 1 Unknown

25 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT01384513 2022-11-17

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Phase 2 Completed

40 enrolled

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Aplastic, Anemia, Refractory, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mastocytosis, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Polycythemia Vera, Recurrence, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

NCT02859402 2022-08-18

RRTCLAlloSCT

Phase 2 Recruiting

34 enrolled

Recurrence, Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell

NCT02761915 2021-08-17

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

17 enrolled 17 charts

CNS

Cytokine Release Syndrome, Neuroblastoma, Recurrence

NCT03661515 2020-05-20

FLAGINEXOR

16 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT01289457 2020-02-24

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Phase 1/2 Completed

282 enrolled 13 charts

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT03126864 2019-11-04

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

Phase 1 Terminated

11 enrolled

Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT00169208 2019-08-28

Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma

Phase 2 Completed

50 enrolled

Lymphoma, Follicular, Recurrence

NCT03916679 2019-04-16

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

Phase 1/2 Unknown

Phase EARLY_PHASE1 Unknown

Gynecologic

Ovarian Neoplasms, Recurrence

NCT03799913 2019-04-10

MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

Gynecologic

Ovarian Neoplasms, Recurrence

NCT03029273 2019-01-17

NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC

Phase 1 Unknown

Thoracic

Lung Neoplasms, Recurrence

NCT02718755 2018-06-26

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Phase 2 Withdrawn

Burkitt Lymphoma, Lymphoma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03208556 2017-09-14

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

Phase 1 Unknown

Recurrence, Lymphoma, B-Cell

NCT01173679 2017-04-14

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

Phase 2 Terminated

10 enrolled 6 charts